CoChat

Chronic inflammation induces telomere dysfunction and accelerates ageing in mice

Open access

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index; 17 of the 36 sources its claims cite were checked for support.

Abstract

Chronic inflammation is associated with normal and pathological ageing. Here we show that chronic, progressive low-grade inflammation induced by knockout of the nfkb1 subunit of the transcription factor NF-κB induces premature ageing in mice. We also show that these mice have reduced regeneration in liver and gut. nfkb1(-/-) fibroblasts exhibit aggravated cell senescence because of an enhanced autocrine and paracrine feedback through NF-κB, COX-2 and ROS, which stabilizes DNA damage. Preferential accumulation of telomere-dysfunctional senescent cells in nfkb1(-/-) tissues is blocked by anti-inflammatory or antioxidant treatment of mice, and this rescues tissue regenerative potential. Frequencies of senescent cells in liver and intestinal crypts quantitatively predict mean and maximum lifespan in both short- and long-lived mice cohorts. These data indicate that systemic chronic inflammation can accelerate ageing via ROS-mediated exacerbation of telomere dysfunction and cell senescence in the absence of any other genetic or environmental factor.

Overview

CoChat Summary

## TL;DR

The paper shows that knocking out nfkb1 in mice causes progressive chronic inflammation, premature ageing, and reduced tissue regeneration, with telomere-dysfunctional senescent cells accumulating in liver and gut. Anti-inflammatory or antioxidant treatment, including ibuprofen or BHA, reduced telomere dysfunction/senescence and rescued regenerative capacity.

## Key findings

  • Chronic inflammation progressed with age in nfkb1−/− mice: at 36 weeks, they had increased splenomegaly, higher plasma IL-6, and more CD3+ immune-cell infiltration in liver and other organs; 43 of 78 NF-κB target genes were upregulated in 36-week-old nfkb1−/− livers.
  • Premature ageing phenotypes were widespread: by 36 weeks, nfkb1−/− mice showed hair loss/greying, scruffy fur, cachexia, reduced fat depots, thinner epidermis, and poorer neuromuscular coordination; their mean and maximum lifespan were reduced.
  • Tissue regeneration was impaired but reversible: after partial hepatectomy, hepatocyte proliferation in nfkb1−/− mice was “drastically reduced” to levels typical of aged wild-type mice, and 1 month of ibuprofen or BHA fully restored liver regenerative capacity; in intestinal crypts, 54-week-old nfkb1−/− mice had decreased stem and progenitor function.
  • Senescence and telomere dysfunction were amplified: nfkb1−/− fibroblasts senesced faster, with more sen-β-gal+ cells, DNA damage foci, mitochondrial superoxide, and stronger SASP; in vivo, TAF frequencies were higher in nfkb1−/− liver and gut and were completely prevented by ibuprofen and rescued by BHA.

## Methods

  • Design: comparative mouse study using nfkb1−/− mice versus wild-type controls, plus additional models (p55Δns/Δns, late-generation terc−/−, dietary restriction, and ICRFa lifespan cohorts) to test links among inflammation, telomere dysfunction, senescence, regeneration, and lifespan.
  • Data/sample: male mice on C57Bl/6 background were studied, often at 36 weeks of age; lifespan cohorts included nfkb1−/− 27, C57Bl/6 AL 310, C57Bl/6 DR 241, ICRFa 2391, and F3TERC−/− 13 mice.
  • Main analysis: histology/immunofluorescence, telomere ImmunoFISH, qPCR/array profiling, ELISA/antibody arrays, organoid crypt culture, partial hepatectomy regeneration assays, and Kaplan–Meier/log-rank survival analysis; group comparisons used t-tests and ANOVA.

## Limitations

  • Stated by the paper: “We did not attempt to rescue lifespan in nfkb1−/− mice by anti-inflammatory treatment because of the known long-term side effects of NSAIDs like ibuprofen.”
  • Stated by the paper: The authors note that the lifespan-rescue question remains unresolved because only medium-term (1–2 months) anti-inflammatory/antioxidant treatment was tested for telomere dysfunction and regeneration.
  • Evident from the text: Much of the causal evidence comes from mouse models and ex vivo fibroblast/crypt assays, so direct applicability to humans is inferential rather than tested here.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/ncomms5172

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Loss of nfkb1 induces an inflammatory phenotype in mice. All data are mean (M) ±s.e.m., 5–6 animals per group, if not otherwise indicated. Significant differences (ANOVA, P<0.05) to young animals are indicated by *, and between wt and nfkb1−/− strains at the same age group by #. (a) IL-6 levels in blood plasma as measured by ELISA at the indicated ages. (b) White pulp (WP) and germinal center (GC) volume densities measured on spleen H&E images at 36 weeks of age. (c) Representative CD3 immunohistochemistry at 36 weeks of age showing increased immune cell infiltrations (arrows) in lung (top), kidney (middle) and liver (bottom) of nfkb1−/−, but not wt, mice. (d) Frequencies of CD3-positive cells in livers at the indicated ages. (e) Frequencies of CD3-positive cells in livers at 32 weeks of age following treatment of mice with ibuprofen or vehicle for 8 weeks. (f) Frequencies of CD3-positive cells in livers at 12 weeks of age following treatment of mice with the antioxidant BHA or vehicle for 4 weeks. (g) Representative α smooth muscle cell actin (α-SMA) immunohistochemistry showing increased pro-fibrotic activity in livers from nfkb1−/− mice. (h) Expression of NF-κB target genes in liver (qPCR array) at the indicated ages, n=4 per group. All genes that are significantly changed (P<0.05) in at least one group are shown. (i) Cytokine expression pattern in liver at 36 weeks of age, n=4 per group. Green star indicates proteins upregulated in nfkb1−/− (P<0.10, t-test), red star indicates that mRNA upregulation (h) was confirmed at protein level, black star indicates that mRNA upregulation was not confirmed at protein level.
Figure 1 Loss of nfkb1 induces an inflammatory phenotype in mice. All data are mean (M) ±s.e.m., 5–6 animals per group, if not otherwise indicated. Significant differences (ANOVA, P<0.05) to young animals are indicated by *, and between wt and nfkb1−/− strains at the same age group by #. (a) IL-6 levels in blood plasma as measured by ELISA at the indicated ages. (b) White pulp (WP) and germinal center (GC) volume densities measured on spleen H&E images at 36 weeks of age. (c) Representative CD3 immunohistochemistry at 36 weeks of age showing increased immune cell infiltrations (arrows) in lung (top), kidney (middle) and liver (bottom) of nfkb1−/−, but not wt, mice. (d) Frequencies of CD3-positive cells in livers at the indicated ages. (e) Frequencies of CD3-positive cells in livers at 32 weeks of age following treatment of mice with ibuprofen or vehicle for 8 weeks. (f) Frequencies of CD3-positive cells in livers at 12 weeks of age following treatment of mice with the antioxidant BHA or vehicle for 4 weeks. (g) Representative α smooth muscle cell actin (α-SMA) immunohistochemistry showing increased pro-fibrotic activity in livers from nfkb1−/− mice. (h) Expression of NF-κB target genes in liver (qPCR array) at the indicated ages, n=4 per group. All genes that are significantly changed (P<0.05) in at least one group are shown. (i) Cytokine expression pattern in liver at 36 weeks of age, n=4 per group. Green star indicates proteins upregulated in nfkb1−/− (P<0.10, t-test), red star indicates that mRNA upregulation (h) was confirmed at protein level, black star indicates that mRNA upregulation was not confirmed at protein level.CC BY · PubMed Central
Figure 2 Premature ageing of nfkb1−/− mice. (a) Kaplan–Meier survival curves (right censored) of wt and nfkb1−/− mice, log-rank test, n≥27. (b) Representative images of wt mice and an nfkb1−/− mouse at the indicated ages showing premature hair greying and scruffy fur in nfkb1−/− mice. (c) Age at maximum body weight in nfkb1−/− and wt mice (n=56 for wt, n=8 for nfkb1−/−, P<0.05, t-test). (d) Representative skin sections of 36-week-old animals, H&E stain. Boxed areas are shown at higher magnification. Mean epidermal thickness at the indicated ages is shown on the right (n≥5). (e) Neuromuscular coordination measured as number of unsuccessful attempts to remain on a straight rod for 60 s (n=6 to 10 per group). All data are M±s.e.m. Significant differences (ANOVA with post hoc Holm–Sidak test, P<0.05) to respective controls of the same genotype are indicated by *, and between wt and nfkb1−/− strains at the same treatment by #.
Figure 2 Premature ageing of nfkb1−/− mice. (a) Kaplan–Meier survival curves (right censored) of wt and nfkb1−/− mice, log-rank test, n≥27. (b) Representative images of wt mice and an nfkb1−/− mouse at the indicated ages showing premature hair greying and scruffy fur in nfkb1−/− mice. (c) Age at maximum body weight in nfkb1−/− and wt mice (n=56 for wt, n=8 for nfkb1−/−, P<0.05, t-test). (d) Representative skin sections of 36-week-old animals, H&E stain. Boxed areas are shown at higher magnification. Mean epidermal thickness at the indicated ages is shown on the right (n≥5). (e) Neuromuscular coordination measured as number of unsuccessful attempts to remain on a straight rod for 60 s (n=6 to 10 per group). All data are M±s.e.m. Significant differences (ANOVA with post hoc Holm–Sidak test, P<0.05) to respective controls of the same genotype are indicated by *, and between wt and nfkb1−/− strains at the same treatment by #.CC BY · PubMed Central
Figure 3 Impaired regeneration in gut and liver of nfkb1−/− mice is ameliorated by treatment with NSAID. Significant differences (ANOVA with post hoc Holm–Sidak test, P<0.05) to respective controls of the same genotype are indicated by *, and between wt and nfkb1−/− strains at the same treatment by #. (a) Representative Ki-67 immunofluorescence (red) images from wt (top) and nfkb1−/− (bottom) livers at 72 h after partial hepatectomy at 12 weeks of age. Mice were pretreated with or without ibuprofen for 4 weeks. (b) Frequencies of Ki-67-positive hepatocytes at 72 h after partial hepatectomy in wt and nfkb1−/− animals. Data are M±s.e.m. from seven animals per group. (c) Frequencies of PCNA-positive hepatocytes at 72 h after partial hepatectomy in wt and nfkb1−/− animals, pretreated or not with the antioxidant BHA for 4 weeks. Data are M±s.e.m. from 7 animals per group. (d) Representative colonic (top) and intestinal (bottom) H&E sections from wt and nfkb1−/− mice aged 36 weeks. (e) Quantification of colonic mucosal thickness (top) and villus length (bottom). Data are M±s.e.m. from 30–100 colonic crypts from 4 animals, P=0.0001, and from 20–60 villi from 3–5 animals, P=0.029. (f) Representative images of single crypts isolated from mice at the indicated age and grown for 10 days in vitro. (g) Frequencies of crypts that grew in vitro. (h) Crypt size (surface area) at day 10 in vitro. Data in (g) and (h) are M±s.e.m. from 20–200 crypts isolated from three animals per group.
Figure 3 Impaired regeneration in gut and liver of nfkb1−/− mice is ameliorated by treatment with NSAID. Significant differences (ANOVA with post hoc Holm–Sidak test, P<0.05) to respective controls of the same genotype are indicated by *, and between wt and nfkb1−/− strains at the same treatment by #. (a) Representative Ki-67 immunofluorescence (red) images from wt (top) and nfkb1−/− (bottom) livers at 72 h after partial hepatectomy at 12 weeks of age. Mice were pretreated with or without ibuprofen for 4 weeks. (b) Frequencies of Ki-67-positive hepatocytes at 72 h after partial hepatectomy in wt and nfkb1−/− animals. Data are M±s.e.m. from seven animals per group. (c) Frequencies of PCNA-positive hepatocytes at 72 h after partial hepatectomy in wt and nfkb1−/− animals, pretreated or not with the antioxidant BHA for 4 weeks. Data are M±s.e.m. from 7 animals per group. (d) Representative colonic (top) and intestinal (bottom) H&E sections from wt and nfkb1−/− mice aged 36 weeks. (e) Quantification of colonic mucosal thickness (top) and villus length (bottom). Data are M±s.e.m. from 30–100 colonic crypts from 4 animals, P=0.0001, and from 20–60 villi from 3–5 animals, P=0.029. (f) Representative images of single crypts isolated from mice at the indicated age and grown for 10 days in vitro. (g) Frequencies of crypts that grew in vitro. (h) Crypt size (surface area) at day 10 in vitro. Data in (g) and (h) are M±s.e.m. from 20–200 crypts isolated from three animals per group.CC BY · PubMed Central
Figure 4 nfkb1−/− aggravates the senescent phenotype in MAFs. All data are M±s.e.m. from 3or 4 independent strains per condition, if not otherwise indicated. Significant differences (ANOVA with post-hoc Holm-Sidak test, P<0.05) to respective controls are indicated by *, and between wt and nfkb1−/− strains at the same treatment/time point by #. (a) Growth of nfkb1−/− and wt MAFs in culture under 21% ambient oxygen. (b) Frequencies of sen-β-Gal-positive MAFs after 10 days under 21% ambient oxygen. (c) ATM/ATR foci frequencies in wt and nfkb1−/− MAF nuclei at the indicated times after 10 Gy IR. (d) Frequencies of sen-β-Gal-positive MAFs at 3 days after induction of senescence by 10 Gy IR and treatment (or not) with the NSAID ibuprofen (ibu, 0.2 mM) or the COX-2 inhibitor NS-398 (2.5 mM). (e) Frequencies of nuclear 53BP1 foci in MAFs at 3 days after 10 Gy IR and treatment (or not) with ibuprofen. (f) Mitochondrial superoxide levels measured by MitoSOX fluorescence in MAFs at day 3 after treatment with/without 10 Gy IR and the p38 inhibitor SB203580 (10 μM) or ibuprofen (0.2 mM). (g) Expression of the COX-2 gene (normalized to actin) in MAFs 3 days after treatment with/without 10 Gy IR. (h) 53BP1 foci frequencies in MAFs treated with the COX-2 inhibitor NS-398 or sham (DMSO) treated. (i) Cellular ROS levels (DHE fluorescence intensity) in MAFs after treatment with/without 10 Gy IR and with NS-398. (j) 53BP1 foci frequencies in MAFs treated with/without 10Gy IR and either scrambled siRNA or one of two siRNAs against COX-2. (k) CELL-ROX fluorescence in MAFs after COX-2 siRNA treatment. One representative experiment out of four per cell type and treatment is shown. (l) Scheme of the bystander experiment. wt or nfkb1−/− MAFs were irradiated to induce senescence and then co-cultured with reporter cells expressing a 53BP1-GFP fusion protein. (m) DNA damage foci in senescent MAFs of the indicated genotype (left, shown by 53BP1 immunofluorescence in red) and in co-cultured reporter fibroblasts (right, foci also contain green 53BP1-GFP fusion protein). (n) Senescent nfkb1−/− MAFs induce more DNA damage in non-senescent bystander cells than senescent wt MAFs. 53BP1-GFP foci frequencies in bystander fibroblasts after the indicated times of co-culture are shown.
Figure 4 nfkb1−/− aggravates the senescent phenotype in MAFs. All data are M±s.e.m. from 3or 4 independent strains per condition, if not otherwise indicated. Significant differences (ANOVA with post-hoc Holm-Sidak test, P<0.05) to respective controls are indicated by *, and between wt and nfkb1−/− strains at the same treatment/time point by #. (a) Growth of nfkb1−/− and wt MAFs in culture under 21% ambient oxygen. (b) Frequencies of sen-β-Gal-positive MAFs after 10 days under 21% ambient oxygen. (c) ATM/ATR foci frequencies in wt and nfkb1−/− MAF nuclei at the indicated times after 10 Gy IR. (d) Frequencies of sen-β-Gal-positive MAFs at 3 days after induction of senescence by 10 Gy IR and treatment (or not) with the NSAID ibuprofen (ibu, 0.2 mM) or the COX-2 inhibitor NS-398 (2.5 mM). (e) Frequencies of nuclear 53BP1 foci in MAFs at 3 days after 10 Gy IR and treatment (or not) with ibuprofen. (f) Mitochondrial superoxide levels measured by MitoSOX fluorescence in MAFs at day 3 after treatment with/without 10 Gy IR and the p38 inhibitor SB203580 (10 μM) or ibuprofen (0.2 mM). (g) Expression of the COX-2 gene (normalized to actin) in MAFs 3 days after treatment with/without 10 Gy IR. (h) 53BP1 foci frequencies in MAFs treated with the COX-2 inhibitor NS-398 or sham (DMSO) treated. (i) Cellular ROS levels (DHE fluorescence intensity) in MAFs after treatment with/without 10 Gy IR and with NS-398. (j) 53BP1 foci frequencies in MAFs treated with/without 10Gy IR and either scrambled siRNA or one of two siRNAs against COX-2. (k) CELL-ROX fluorescence in MAFs after COX-2 siRNA treatment. One representative experiment out of four per cell type and treatment is shown. (l) Scheme of the bystander experiment. wt or nfkb1−/− MAFs were irradiated to induce senescence and then co-cultured with reporter cells expressing a 53BP1-GFP fusion protein. (m) DNA damage foci in senescent MAFs of the indicated genotype (left, shown by 53BP1 immunofluorescence in red) and in co-cultured reporter fibroblasts (right, foci also contain green 53BP1-GFP fusion protein). (n) Senescent nfkb1−/− MAFs induce more DNA damage in non-senescent bystander cells than senescent wt MAFs. 53BP1-GFP foci frequencies in bystander fibroblasts after the indicated times of co-culture are shown.CC BY · PubMed Central
Figure 5 Inflammation causes telomere dysfunction and senescence in vivo. All data are M±s.e.m. from 5-6 animals per group. Significant differences (ANOVA with post-hoc Holm-Sidak test, P<0.05) to control (young) animals of the same genotype are indicated by *, and between wt and transgenic animals at the same age/treatment by #. (a) Representative immunoFISH image from a crypt cross-section (nfkb1−/−, 36 weeks). (b) Representative immunoFISH image from a nfkb1−/− hepatocyte nucleus at 36 weeks of age. In (a) and (b), images are maximum intensity projections of at least 60 planes. Amplified images on the right are from single Z planes where colocalization was found. Graphs represent quantification of γH2A.X and telomere signals in selected regions of interest (dotted lines). Scale bar: 10 μm. (c) Frequencies of TAF in hepatocytes from nfkb1−/− and wt livers at the indicated ages. 32 weeks old animals received either 8 weeks ibuprofen or sham treatment. (d) Frequencies of TAF in nfkb1−/− and wt intestinal crypt enterocytes at the indicated ages. 32 weeks old animals received either 8 weeks ibuprofen or sham treatment. (e) TAF frequencies in livers from p55Δns/Δns mice at 20 weeks of age. (f) Representative 4-HNE immunohistochemistry in wt (top) and nfkb1−/− (bottom) liver (centrilobular area). (g) Frequencies of 4-HNE-positive hepatocytes at the indicated ages. (h) Representative double immunofluorescence image of nfkb1−/− liver. green: γH2AX, red: 4-HNE, blue: DAPI. Cells that are both positive for γH2AX+ and 4-HNE+ are marked by arrows. (i) Frequencies of TAF in hepatocytes from nfkb1−/− and wt livers at 12 weeks of age. Animals received either 4 weeks BHA or sham treatment. (j) Expression of oxidative stress-related genes in liver (qPCR array) of wt, nfkb1−/− and late generation terc−/− mice, n=4 per group. All genes that are significantly changed (P<0.05) in at least one group are shown. (k) NF-κB activity in wt, nfkb1−/− and late generation terc−/− liver tissue. (l) Expression of NF-κB target genes in wt and late generation terc−/− liver (qPCR array). n=4 per group. All genes that are significantly changed (P<0.05) in at least one group are shown. Gene names in green: expression changed in the same direction in nfkb1−/− and terc−/− livers. Gene names in red: expression changed in opposite direction (comp. Fig. 1h).
Figure 5 Inflammation causes telomere dysfunction and senescence in vivo. All data are M±s.e.m. from 5-6 animals per group. Significant differences (ANOVA with post-hoc Holm-Sidak test, P<0.05) to control (young) animals of the same genotype are indicated by *, and between wt and transgenic animals at the same age/treatment by #. (a) Representative immunoFISH image from a crypt cross-section (nfkb1−/−, 36 weeks). (b) Representative immunoFISH image from a nfkb1−/− hepatocyte nucleus at 36 weeks of age. In (a) and (b), images are maximum intensity projections of at least 60 planes. Amplified images on the right are from single Z planes where colocalization was found. Graphs represent quantification of γH2A.X and telomere signals in selected regions of interest (dotted lines). Scale bar: 10 μm. (c) Frequencies of TAF in hepatocytes from nfkb1−/− and wt livers at the indicated ages. 32 weeks old animals received either 8 weeks ibuprofen or sham treatment. (d) Frequencies of TAF in nfkb1−/− and wt intestinal crypt enterocytes at the indicated ages. 32 weeks old animals received either 8 weeks ibuprofen or sham treatment. (e) TAF frequencies in livers from p55Δns/Δns mice at 20 weeks of age. (f) Representative 4-HNE immunohistochemistry in wt (top) and nfkb1−/− (bottom) liver (centrilobular area). (g) Frequencies of 4-HNE-positive hepatocytes at the indicated ages. (h) Representative double immunofluorescence image of nfkb1−/− liver. green: γH2AX, red: 4-HNE, blue: DAPI. Cells that are both positive for γH2AX+ and 4-HNE+ are marked by arrows. (i) Frequencies of TAF in hepatocytes from nfkb1−/− and wt livers at 12 weeks of age. Animals received either 4 weeks BHA or sham treatment. (j) Expression of oxidative stress-related genes in liver (qPCR array) of wt, nfkb1−/− and late generation terc−/− mice, n=4 per group. All genes that are significantly changed (P<0.05) in at least one group are shown. (k) NF-κB activity in wt, nfkb1−/− and late generation terc−/− liver tissue. (l) Expression of NF-κB target genes in wt and late generation terc−/− liver (qPCR array). n=4 per group. All genes that are significantly changed (P<0.05) in at least one group are shown. Gene names in green: expression changed in the same direction in nfkb1−/− and terc−/− livers. Gene names in red: expression changed in opposite direction (comp. Fig. 1h).CC BY · PubMed Central
Figure 6 Accumulation of senescent cells predicts lifespan in mice over a wide range of interventions. (a) Maximum lifespan of males in different cohorts of mice under AL feeding and dietary restriction (DR). See Methods for cohort description. (b–f) Frequencies of senescent centrilobular hepatocytes measured as γH2AX+ PCNA− cells (b), cells with >1 TAF (c), with >2TAFs (d), Sen-β-Gal positive cells (e) or 4-HNE- positive cells (f) versus relative age (calculated as % of maximum lifespan completed). Symbol colours indicate the same strains as in (a), triangle indicates a strain under dietary restriction. Data are M±s.e.m. from at least 3 mice per age group. (g) Maximum lifespan per cohort versus rate of accumulation of senescent hepatocytes, calculated by linear regression of senescent cell frequencies against age. Symbol outlines indicate strain/condition as before. Symbol fills indicate the senescence marker used: outline colour: γ-H2AX+ PCNA−, pink: sen-β-Gal, white: >1TAF, grey: >2TAFs. (h) Maximum lifespan versus rate of accumulation of senescent crypt enterocytes. Symbols as before.
Figure 6 Accumulation of senescent cells predicts lifespan in mice over a wide range of interventions. (a) Maximum lifespan of males in different cohorts of mice under AL feeding and dietary restriction (DR). See Methods for cohort description. (b–f) Frequencies of senescent centrilobular hepatocytes measured as γH2AX+ PCNA− cells (b), cells with >1 TAF (c), with >2TAFs (d), Sen-β-Gal positive cells (e) or 4-HNE- positive cells (f) versus relative age (calculated as % of maximum lifespan completed). Symbol colours indicate the same strains as in (a), triangle indicates a strain under dietary restriction. Data are M±s.e.m. from at least 3 mice per age group. (g) Maximum lifespan per cohort versus rate of accumulation of senescent hepatocytes, calculated by linear regression of senescent cell frequencies against age. Symbol outlines indicate strain/condition as before. Symbol fills indicate the senescence marker used: outline colour: γ-H2AX+ PCNA−, pink: sen-β-Gal, white: >1TAF, grey: >2TAFs. (h) Maximum lifespan versus rate of accumulation of senescent crypt enterocytes. Symbols as before.CC BY · PubMed Central

Verification

Claims the paper makes

11 Valid · 1 Not valid · 9 Not checked · 56 Own results and interpretations

32 more claims

Create a free account to see all 77 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 36
  • Probably not a substantial claim. 10

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

13 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 73 references

Cited by

Items 301–400 of 806

Metadata

Authors
Jurk, D., Wilson, C., Passos, J. F., Oakley, F., Correia-Melo, C., Greaves, L., Saretzki, G., Fox, C., Lawless, C., Anderson, R., Hewitt, G., Pender, S. L., Fullard, N., Nelson, G., Mann, J., van de Sluis, B., Mann, D. A., & von Zglinicki, T.
Affiliations
  • Newcastle University (GB)
  • Southampton General Hospital (GB)
  • University Medical Center Groningen (NL)
Corresponding author
von Zglinicki, Thomas
Venue
Nature Communications
Published
2014-06-24
Volume
5
Issue
1
Pages
4172-4172
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2125764628
Cited by
819
References
73
Citations by year
2026: 46 · 2025: 67 · 2024: 72 · 2023: 72 · 2022: 67 · 2021: 82 · 2020: 76 · 2019: 77 · 2018: 72 · 2017: 56 · 2016: 71 · 2015: 55 · 2014: 5
FWCI
20.95
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • ePrints Soton (University of Southampton) (submittedVersion)
  • Durham Research Online (Durham University) (submittedVersion, cc-by)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
  • Wellcome Trust (G0900535, WT084961MA)
  • National Institute for Health and Care Research
  • European Commission (223151)
  • National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/K000748/1)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Medical Research Council (MR/K001949/1, G0900535, MK/K001949/1, G0700890, MR/L016354/1)
  • Biotechnology and Biological Sciences Research Council (BB/C008200/1, BB/F010966/1, BB/K017314/1, BB/H022384/1, BB/I020748/1)
  • NIHR Newcastle Biomedical Research Centre
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
Keywords
chronic inflammation, premature aging, telomere dysfunction, NF-κB, cellular senescence, reactive oxygen species, cyclooxygenase-2, DNA damage, tissue regeneration, liver regeneration, intestinal crypts, lifespan, antioxidant treatment, anti-inflammatory therapy
MeSH terms
Animals, Chronic Disease, DNA Damage, Fibroblasts, Inflammation, Liver Regeneration, Regeneration, NF-kappa B, Cellular Senescence, Reactive Oxygen Species, Mice, Knockout, Aging, Premature, Feedback, Physiological, Mice, Cyclooxygenase 2, NF-kappa B p50 Subunit, Telomere Homeostasis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.